Free Trial

Plus Therapeutics Q4 2023 Earnings Report

Plus Therapeutics logo
$0.97 -0.19 (-16.21%)
As of 03:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Plus Therapeutics EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Plus Therapeutics Revenue Results

Actual Revenue
$1.31 million
Expected Revenue
$1.26 million
Beat/Miss
Beat by +$50.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Plus Therapeutics Earnings Headlines

Plus Therapeutics price target lowered to $5.50 from $8 at H.C. Wainwright
Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

View Plus Therapeutics Profile

More Earnings Resources from MarketBeat